These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1469890)

  • 41. Epidemiology of gastrointestinal cancers in Scandinavia. I. Report on Denmark, Finland, Norway, and Sweden.
    Ringertz N
    Natl Cancer Inst Monogr; 1967 Jul; 25():219-39. PubMed ID: 6033054
    [No Abstract]   [Full Text] [Related]  

  • 42. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
    Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL
    Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Precancerous lesions of the human esophagus: multiparametric study of esophageal biopsies from a high-risk population in Linxian, China.
    Yang K; Liu Y; Lipkin M; Wang G; Mou D; Li G; Li J; Li P
    J Cell Biochem Suppl; 1992; 16G():187-94. PubMed ID: 1469900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemoprevention trials of GI cancers in Asia.
    Li JW; Tan MT; Ang TL; Teo EK
    Best Pract Res Clin Gastroenterol; 2015 Dec; 29(6):967-78. PubMed ID: 26651257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Etiological aspects of cancer of the gastrointestinal tract.
    Lowenfels AB
    Surg Gynecol Obstet; 1973 Aug; 137(2):291-9. PubMed ID: 4124850
    [No Abstract]   [Full Text] [Related]  

  • 47. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
    Lipkin M
    J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastrointestinal Malignancies.
    Sonnenberg WR
    Prim Care; 2017 Dec; 44(4):721-732. PubMed ID: 29132531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Smoking and cancer of the alimentary tract in Poland.
    Staszewski J
    Br J Cancer; 1969 Jun; 23(2):247-53. PubMed ID: 5788032
    [No Abstract]   [Full Text] [Related]  

  • 50. Chemoprevention of gastrointestinal cancer.
    Montoya RG; Wargovich MJ
    Cancer Metastasis Rev; 1997; 16(3-4):405-19. PubMed ID: 9433648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Field defects in progression to gastrointestinal tract cancers.
    Bernstein C; Bernstein H; Payne CM; Dvorak K; Garewal H
    Cancer Lett; 2008 Feb; 260(1-2):1-10. PubMed ID: 18164807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract.
    Bornschein J; Bird-Lieberman EL; Malfertheiner P
    Dig Dis; 2019; 37(5):381-393. PubMed ID: 30970344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermediate biomarkers in upper aerodigestive tract and lung chemoprevention trials.
    Benner SE; Hong WK; Lippman SM; Lee JS; Hittelman WM
    J Cell Biochem Suppl; 1992; 16G():33-8. PubMed ID: 1469903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the Dysplasia Trial in Linxian, China.
    Dawsey SM; Wang GQ; Taylor PR; Li JY; Blot WJ; Li B; Lewin KJ; Liu FS; Weinstein WM; Wiggett S
    Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):167-72. PubMed ID: 8049639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Occurrence and prevalence of malignant neoplasms of the digestive organs in the German Democratic Republic].
    Berndt H; Váradi E
    Z Arztl Fortbild (Jena); 1978 May; 72(9):450-5. PubMed ID: 676387
    [No Abstract]   [Full Text] [Related]  

  • 56. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach.
    Souza RF; Spechler SJ
    CA Cancer J Clin; 2005; 55(6):334-51. PubMed ID: 16282279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastrointestinal cytology.
    Geisinger KR; Wang HH; Ducatman BS; Teot LA
    Clin Lab Med; 1991 Jun; 11(2):403-41. PubMed ID: 1873965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
    Bazuro GE; Torino F; Gasparini G; Capurso L
    Minerva Gastroenterol Dietol; 2008 Dec; 54(4):429-44. PubMed ID: 19047983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.